COVID-19 Saliva Screening Test Potential Market - Global Industry Analysis

COVID-19 Saliva Screening Test Potential Market - By Technology (Fluorescence-labelled antigen, RT-PCR, and CRISPR-Cas9), By Mode of Testing (Centralized Testing and Decentralized Testing), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2028

Published Date: 12-Jul-2021 Category: Biotechnology Report Format : PDF Pages: 110 Report Code: ZMR-6469 Status : Published

The global COVID-19 Saliva Screening Test Potential market accrued earnings worth approximately 2,960 (USD Billion) in 2020 and is predicted to gain revenue of about 4,733 (USD Billion) by 2028, is set to record a CAGR of nearly 4.7% over the period from 2021 to 2028.

Description

The global COVID-19 Saliva Screening Test Potential market accrued earnings worth approximately 2,960 (USD Billion) in 2020 and is predicted to gain revenue of about 4,733 (USD Billion) by 2028, is set to record a CAGR of nearly 4.7% over the period from 2021 to 2028. The report offers assessment and analysis of the COVID-19 Saliva Screening Test Potential market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Report Scope :

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

COVID-19 Saliva Screening Test Potential Market: Overview

According to WHO, SARS-CoV-2 is the key cause of COVID-19 and has spread across nearly 235 nations. Moreover, large-scale spread of the pandemic resulted in global lockdown in 2019-2020. Furthermore, WHO has recommended nasopharyngeal and oropharyngeal swab for quantitative assessment of SARS-CoV-2 RNA via RTPCR (real-time reverse transcription PCR). Reportedly, the virus is found to be constantly present in saliva & RTPCR of saliva specimens. Moreover, RTPCR of saliva specimens provides more benefits over oropharyngeal swab and nasopharyngeal swab such as saliva self-collection, cost-efficiency, and avoiding services of health workers for collecting specimen.

Additionally, salivary diagnosis includes “Salivaomics” that represents identifying of myriad “omics” constituting of salivary proteome, microRNA, microbiome, transcriptome, metabolome, and transcriptome. As per NCBI, saliva tests are found to be quick, cost-efficient, and highly sensitive & analytic in determination of oral ailments, viral infections, and human stress tests. Hence, saliva is considered to be effective diagnostic Biofluid for COVID-19 tests.

COVID-19 Saliva Screening Test Potential Market: Growth Dynamics

Accurate diagnosing of COVID 19 is key for containing disease in clinics and community set-up and testing of salivary specimens of individuals have proved to be technically advantageous as compared to testing of blood or any other body fluids. This, in turn, will drive growth of COVID-19 saliva screening test potential market over the years ahead. In addition to this, saliva can be easily self-collected by children & adults with patient spitting in sterile container. Hence, collection of saliva eliminates requirement of services of healthcare professionals along with reducing nosocomial infections. This, in turn, will drive industry trends. Apparently, saliva screening minimizes costs and time related to specimen collection, thereby raising number of tests of patients along with supporting mass screening. This will create lucrative growth avenues for COVID-19 saliva screening test potential industry over the years ahead.

Furthermore, saliva specimen collection can be made when outpatient clinics, household areas, and community sites are not available. For the record, from saliva screening test results demonstrated by Australian researchers in June 2021 at Royal Melbourne Hospital, it was found that new saliva tests using infrared light technology had ability to detect COVID-19 within five minutes. Such breakthroughs is likely to help the market explore new growth frontlines in the near future. Salivary specimen collection is non-invasive and can minimize exposure of health workers to COVID-19 disease to a large extent, thereby steering growth of industry sphere. The saliva collection can also be used for sequential determination of viral load and this will scale up market value in the next couple of years.

Global COVID-19 Saliva Screening Test Potential Market

Regional Landscape

North American To Retain Market Domination Over 2021-2028

The growth of COVID-19 saliva screening test potential industry in North America during forecast period can be credited to launching of myriad products by startups. Apart from this, presence of key participants in the sub-continent involved in development of diagnostics & screening tests is likely to contribute majorly towards regional market size over the upcoming years.

Competitive Insights

Key players leveraging market surge and profiled in study include ARUP Labs, Psomagen, Inc., Vatic Health, MOgene, Fluidigm Corporation, Phosphorus Diagnostics LLC, Quidel Corporation, Abbot Laboratories, FLuroTech Ltd., LumiraDX, Gravity Diagnostics, Ambry Genetics, and DxTerity Diagnostics, Inc.

The global COVID-19 Saliva Screening Test Potential Market is segmented as follows:

By Technology

  • Fluorescence-labelled antigen
  • RT-PCR
  • CRISPR-Cas9

By Mode of Testing

  • Centralized Testing
  • Decentralized Testing

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. COVID-19 Saliva Screening Test Potential Market, 2018–2028(USD Billion)
    • 2.2. COVID-19 Saliva Screening Test Potential Market: Snapshot
  • Chapter 3. Global COVID-19 Saliva Screening Test Potential Market– End-Use Analysis
    • 3.1. COVID-19 Saliva Screening Test Potential Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Salivary specimen cullection is non-invasive and can minimize exposure of health workers to COVID-19 disease to a large extent, thereby embellishing growth of market.
      • 3.2.2. The saliva cullection can also be used for sequential determination of viral load and this will promulgate market value in the next couple of years.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Technology
      • 3.4.2. Market attractiveness analysis By Mode of Testing
  • Chapter 4. Global COVID-19 Saliva Screening Test Potential Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global COVID-19 Saliva Screening Test Potential Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global COVID-19 Saliva Screening Test Potential Market– Technology Analysis
    • 5.1. Global COVID-19 Saliva Screening Test Potential Market overview: By Technology
      • 5.1.1. Global COVID-19 Saliva Screening Test Potential Market share, By Technology, 2020 and 2028
    • 5.2. Fluorescence-labelled antigen
      • 5.2.1. Global COVID-19 Saliva Screening Test Potential Market by Fluorescence-labelled antigen, 2018–2028(USD Billion)
    • 5.3. RT-PCR
      • 5.3.1. Global COVID-19 Saliva Screening Test Potential Market by RT-PCR, 2018–2028(USD Billion)
    • 5.4. CRISPR-Cas9
      • 5.4.1. Global COVID-19 Saliva Screening Test Potential Market by CRISPR-Cas9, 2018–2028(USD Billion)
  • Chapter 6. Global COVID-19 Saliva Screening Test Potential Market– Mode of Testing Analysis
    • 6.1. Global COVID-19 Saliva Screening Test Potential Market overview: By Mode of Testing
      • 6.1.1. Global COVID-19 Saliva Screening Test Potential Market share, By Mode of Testing, 2020 and 2028
    • 6.2. Centralized Testing
      • 6.2.1. Global COVID-19 Saliva Screening Test Potential Market by Centralized Testing, 2018–2028(USD Billion)
    • 6.3. Decentralized Testing
      • 6.3.1. Global COVID-19 Saliva Screening Test Potential Market by Decentralized Testing, 2018–2028(USD Billion)
  • Chapter 7. Company Profiles
    • 7.1. ARUP Labs
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Psomagen, Inc.
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Vatic Health
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Development
    • 7.4. MOgene
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Development
    • 7.5. Fluidigm Corporation
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Phosphorus Diagnostics LLC
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Quidel Corporation
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Abbot Laboratories
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. FLuroTech Ltd.
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. LumiraDX
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfolio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development
    • 7.11. Gravity Diagnostics
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfolio
      • 7.11.4. Business Strategy
      • 7.11.5. Recent Development
    • 7.12. Ambry Genetics
      • 7.12.1. Overview
      • 7.12.2. Financials
      • 7.12.3. Product Portfolio
      • 7.12.4. Business Strategy
      • 7.12.5. Recent Development
    • 7.13. DxTerity Diagnostics, Inc.
      • 7.13.1. Overview
      • 7.13.2. Financials
      • 7.13.3. Product Portfolio
      • 7.13.4. Business Strategy
      • 7.13.5. Recent Development

Table Of Figures

List of Figures

1. Market research Type
2. Market research methodology
3. Global COVID-19 Saliva Screening Test Potential Market, 2018–2028(USD Billion)
4. Porter’s Five Forces Analysis
5. Global COVID-19 Saliva Screening Test Potential Marketattractiveness, By Technology
6. Global COVID-19 Saliva Screening Test Potential Marketattractiveness, By Mode of Testing
7. Global COVID-19 Saliva Screening Test Potential Marketshare by Technology ,2020 and 2028 (USD Billion)
8. Global COVID-19 Saliva Screening Test Potential Marketby Fluorescence-labelled antigen, 2018–2028(USD Billion)
9. Global COVID-19 Saliva Screening Test Potential Marketby RT-PCR, 2018–2028(USD Billion)
10. Global COVID-19 Saliva Screening Test Potential Marketby CRISPR-CaS9, 2018–2028(USD Billion)
11. Global COVID-19 Saliva Screening Test Potential Marketshare by Mode of Testing ,2020 and 2028 (USD Billion)
12. Global COVID-19 Saliva Screening Test Potential Marketby Centralized Testing, 2018–2028(USD Billion)
13. Global COVID-19 Saliva Screening Test Potential Marketby Decentralized Testing, 2018–2028(USD Billion)
14. Global COVID-19 Saliva Screening Test Potential Marketshare, by Region, 2020 and 2028
15. North America COVID-19 Saliva Screening Test Potential Market, 2018–2028(USD Billion)
16. Europe COVID-19 Saliva Screening Test Potential Market, 2018–2028(USD Billion)
17. Asia Pacific COVID-19 Saliva Screening Test Potential Market, 2018–2028(USD Billion)
18. Latin America COVID-19 Saliva Screening Test Potential Market, 2018–2028(USD Billion)
19. The Middle East and Africa COVID-19 Saliva Screening Test Potential Market, 2018–2028(USD Billion)
 


Table Of Tables

List of Tables

1. Global COVID-19 Saliva Screening Test Potential Market: snapshot
2. Drivers of the COVID-19 Saliva Screening Test Potential Market: impact analysis
3. North America COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
4. North America COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
5. The U.S. COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
6. The U.S. COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
7. Rest of North America COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
8. Rest of North America COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
9. Europe COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
10. Europe COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
11. UK COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
12. UK COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
13. France COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
14. France COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
15. Germany COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
16. Germany COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
17. Rest of Europe COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
18. Rest of Europe COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
19. Asia Pacific COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
20. Asia Pacific COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
21. China COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
22. China COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
23. Japan COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
24. Japan COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
25. India COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
26. India COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
27. Rest of Asia Pacific COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
28. Rest of Asia Pacific COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
29. Latin America COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
30. Latin America COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
31. Brazil COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
32. Brazil COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
33. Rest of Latin America COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
34. Rest of Latin  America COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
35. The Middle East and Africa COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
36. The Middle East and Africa COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
37. Saudi Arabia COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
38. Saudi Arabia COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
39. South Africa COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
40. South Africa COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)
41. Rest of the Middle East & Africa COVID-19 Saliva Screening Test Potential Market revenue, By Technology  ,2018–2028(USD Billion)
42. Rest of the Middle East & Africa COVID-19 Saliva Screening Test Potential Market revenue, By Mode of Testing  ,2018–2028(USD Billion)

 
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Accurate diagnosing of COVID 19 is key for containing disease in clinics and community set-up and testing of salivary specimens of individuals have proved to be technically advantageous as compared to testing of blood or any other body fluids. This, in turn, will drive growth of COVID-19 saliva screening test potential market over the years ahead. In addition to this, saliva can be easily self-collected by children & adults with patient spitting in sterile container. Hence, collection of saliva eliminates requirement of services of healthcare professionals along with reducing nosocomial infections. This, in turn, will drive industry trends. Apparently, saliva screening minimizes costs and time related to specimen collection, thereby raising number of tests of patients along with supporting mass screening. This will create lucrative growth avenues for COVID-19 saliva screening test potential industry over the years ahead.

Furthermore, saliva specimen collection can be made when outpatient clinics, household areas, and community sites are not available. For the record, from saliva screening test results demonstrated by Australian researchers in June 2021 at Royal Melbourne Hospital, it was found that new saliva tests using infrared light technology had ability to detect COVID-19 within five minutes. Such breakthroughs is likely to help the market explore new growth frontlines in the near future. 

 

According to Zion market research report, the global COVID-19 Saliva Screening Test Potential market accrued earnings worth approximately 2,960 (USD Billion) in 2020 and is predicted to gain revenue of about 4,733 (USD Billion) by 2028, is set to record a CAGR of nearly 4.7% over the period from 2021 to 2028.

North America will contribute lucratively towards the global market size over the estimated timeline. The regional market surge is due to launching of myriad products by startups. Apart from this, presence of key participants in the sub-continent involved in development of diagnostics & screening tests is likely to contribute majorly towards regional market size over the upcoming years.

 

The key market participants include ARUP Labs, Psomagen, Inc., Vatic Health, MOgene, Fluidigm Corporation, Phosphorus Diagnostics LLC, Quidel Corporation, Abbot Laboratories, FLuroTech Ltd., LumiraDX, Gravity Diagnostics, Ambry Genetics, and DxTerity Diagnostics, Inc.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed